Pharmacodynamics: Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. It inhibits multiple intracellular kinases (C-RAF, BRAF, and mutant BRAF V600E) and cell surface receptor tyrosine kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are implicated in tumor cell signaling, apoptosis, and tumor angiogenesis. By selectively binding to these enzymatic targets, Sorafenib disrupts the downstream RAF/MEK/ERK signaling pathway, driving malignant cell apoptosis and suppressing tumor vessel formation.
Pharmacokinetics: Following oral administration of Soranib tablets, the mean absolute bioavailability of sorafenib ranges from 38% to 49%. Peak plasma concentration (Cmax) is attained approximately 3 hours post-dose. Plasma protein binding of sorafenib (primarily to serum albumin) is extremely high at approximately 99.5%. Sorafenib undergoes oxidative metabolism in the liver mediated primarily by CYP3A4, as well as glucuronidation mediated by UGT1A9. The main circulating metabolite in plasma is the pyridine N-oxide, which demonstrates in vitro potency similar to that of sorafenib. Excretion occurs mainly through the feces (approx. 77%, with 51% as unchanged drug) and urine (approx. 19% as glucuronidated metabolites). The elimination half-life (T1/2) ranges from 25 to 48 hours, enabling sustained therapeutic drug levels with twice-daily administration.